Survival in Dialysis or Plasma Exchange Treated Patients for Multiple Myeloma – A Single Centre 25 Year Experience by Petra Smajić et al.
SEEMEDJ 2020, VOL 4, NO. 1 Survival of Multiple Myeloma Patients Undergoing Dialysis 
25 Southeastern European Medical Journal, 2020; 4(1) 
 
Original article 
Survival of Multiple Myeloma Patients Undergoing Dialysis or Plasma 
Exchange - A Single Centre’s 25-Year Experience 1 
Petra Smajić* 1, Ema Schönberger 1, Vlatka Periša 1,2, Jasminka Sinčić Petričević 1,2, Lada Zibar 1,3, Kristina 
Kralik 1  
1 Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Croatia 
2 University Hospital Centre Osijek, Croatia 
3 Merkur University Hospital, Zagreb, Croatia 
 
*Corresponding author: Petra Smajić, smajicpetra@gmail.com 
 
 
Received: Feb 19, 2020; revised version accepted: Mar 18, 2020; published: Apr 27, 2020 
  
KEYWORDS: multiple myeloma, kidney failure, haemodialysis, plasma exchange, survival 
 
Abstract 
Aim: Multiple myeloma (MM) patients might require haemodialysis (HD) and/or plasma exchange 
(PE) in cases of acute kidney injury (AKI) and/or chronic kidney disease (CKD) and/or other 
indications. The study analysed the survival of MM patients who required HD and/or PE. 
Subjects and methods: All 144 patients treated for MM at the University Hospital Centre Osijek 
between 1994 and 2018 (of whom 47.9 % were men) were included in the study. Data were collected 
from medical records. MedCalc Statistical Software version 17.8.2 was used for the statistical analysis, 
with significance set at α = 0.05. 
Results: Forty-three of 144 MM patients (29.9 %) were treated with HD and/or PE. Male patients 
required HD or PE more often than female patients (62.8 % vs 37.2 %, P = 0.02). Patients who did not 
require HD or PE were significantly older at the time of their death than the patients treated with HD 
or PE [75 (interquartile range, IQR, 72 – 77) vs 72 (IQR 66 – 75) years; P = 0.009, Mann-Whitney test]. 
Among all patients who required acute or chronic HD, PE or a combination of the treatments, the 
longest life span was found in 17 patients who were treated with chronic HD (median 12 months, IQR 
8 – 58). 
Conclusion: Kidney failure requiring HD or PE in MM was associated with a significantly shorter life 
span in comparison with other MM patients. Chronic HD patients had the longest survival among 
patients who required acute or chronic HD, PE or a combination of the treatments. In general, MM 
patients in need for HD and/or PE had poor survival. 
(Smajić* P, Schönberger E, Periša V, Sinčić Petričević J, Zibar L, Kralik K. Survival of Multiple Myeloma 
Patients Undergoing Dialysis or Plasma Exchange - A Single Centre’s 25-Year Experience. SEEMEDJ 
2020; 4(1); 25-31) 
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Introduction 
Multiple myeloma (MM) represents malignant 
plasma cell proliferation. Tumours, their 
products and the reactions of the host that they 
produce lead to a number of dysfunctional 
organ conditions and symptoms, such as bone-
related pain or fractures, kidney failure, 
susceptibility to infections, anaemia, 
hypercalcemia and sometimes clotting 
irregularities, neurological symptoms and 
symptoms of hyperviscosity (1).  
Kidney failure occurs in nearly 25 % of the 
patients, while in more than half of MM patients, 
there is some kidney pathology. Hypercalcemia, 
deposition of amyloid in glomeruli, 
hyperuricemia, recurrent infections and kidney 
infiltration with tumour cells contribute to kidney 
disorders (1). In most cases, kidney damage is 
associated with immunoglobulin (Ig) and it 
includes the following conditions:  light chain 
cast nephropathy (LCCN), also known as 
myeloma kidney, monoclonal immunoglobulin 
deposit disease and light chain amyloidosis (2). 
An increased quantity of light chains overloads 
tubular cells, which causes tubular damage, 
resulting in direct toxic effects of the light chain 
or indirect release of cell lysosomal enzymes. It 
can also cause Fanconi syndrome by the 
formation of crystalline inclusions in the 
proximal tubules, resulting in a high loss of 
glucose and amino acids as well as irregularities 
of acidification and urea concentration (1, 2). 
Plasma exchange (PE) has been suggested as a 
treatment option for LCCN in order to prevent 
kidney failure. Some retrospective studies have 
shown that PE can prevent acute kidney injury 
(AKI), which can verge into chronic kidney 
disease (CKD) and the need for dialysis (3), while 
other studies have considered PE as a treatment 
that does not have any effect on overall survival 
or need for haemodialysis (2, 4). Other treatment 
options for patients with MM and renal failure 
include bortezomib-based therapies or the use 
of high cut-off dialysis filters to remove free light 
chains (5). The administration of peritoneal 
dialysis and kidney transplant in MM patients 
with kidney failure are controversial treatment 
procedures because of their low rate of survival 
and poor tolerance of therapy (6). At the 
University Hospital Centre Osijek, a proportion of 
MM patients were treated with acute or chronic 
HD, PE or a combination of the treatments. The 
focus of the study was to analyse the outcome 
in MM patients who required HD or PE. 
 
Subjects and methods  
The retrospective study included all 144 patients 
treated at the University Hospital Centre Osijek 
for MM during the period between 1994 and 
2018. Available patients’ data were collected 
from medical records at the Department of 
Hematology, the Department of Nephrology 
and from the register of deaths at the Clinical 
Department of Pathology and Forensic Medicine 
of the University Hospital Centre Osijek. The 
study was conducted between June 2017 and 
February 2018. MM diagnosis was confirmed if 
the bone marrow analysis showed 
plasmacytosis (> 30 %) or if plasmacytosis > 10 % 
was accompanied by monoclonal paraprotein in 
serum and/or urine and osteolytic lesions or 
light chains in serum were present. Criteria for 
the start of HD treatment were AKI or clinical and 
laboratory signs of CKD that required 
substitution of renal function. PE was performed 
for hyperviscosity to remove the light chains. 
Statistical methods 
 
Category data were represented by absolute 
and relative frequencies. The numerical data 
were described as median, minimum, maximum 
and interquartile range (IQR). Differences in 
nominal variables were tested by Fisher’s exact 
test. Differences in numeric variables, due to 
deviations from normal distribution, were tested 
by Mann-Whitney's U Test. All P values were 
double-sided. The level of significance was set 
at α = 0.05. MedCalc Statistical Software version 
17.8.2 was used for the statistical analysis 
(MedCalc Software bvba, Ostend, Belgium; 
http://www.medcalc.org; 2017).
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Results 
The study included 144 MM patients, 43 (29.9 %) 
of whom required HD or PE. Male patients 
needed HD or PE significantly more often (27 of 
69, 62.8 %) than female patients (16 of 75, 37.2 %), 
P = 0.02 (Fisher's exact test). 
 
Up to the time of the study, 95 MM patients died 
(66 %), and at a significantly higher rate if a 
patient needed HD or PE (34 of 43, 79.1 %) than 
those who were not candidates for the 
treatments (61 of 101, 60.4 %), P = 0.03 (Fisher’s 
exact test) (Table 1). 
 
Table 1. Characteristics of patients (N = 144) with multiple myeloma (MM) with regard to 
haemodialysis (HD) or plasma exchange (PE) treatment and overall survival at the time of study 
 Number of (%) patients 
P* 
 
MM patients who 
required HD or PE 
treatment (n = 43, 29.9 %) 
MM patients who did 
not required HD or PE 
treatment  
(n = 101, 70.1 %) 
Total 
Gender      
Male 27 (62.8) 42 (41.6) 69 (47.9) 
0.02 
Female 16 (37.2) 59 (58.4) 75 (52.1) 
Overall survival     
Alive 9 (20.9) 40 (39.6) 49 (34) 
0.03 
Deceased 34 (79.1) 61 (60.4) 95 (66) 
Total 43 (100) 101 (100) 144 (100)  
*Fisher’s exact test 
Among 43 MM patients who required HD or PE 
treatment, 12 (28 %) were treated only with acute 
HD, 11 (26 %) were treated only with chronic HD 
and 8 (19 %) only with PE. Seven (16 %) MM 
patients were treated with both acute HD and  
PE, 1 (2 %) MM patient was treated with both 
chronic HD and PE and 1 (2 %) with both acute 
and chronic HD. Finally, there were 3 (7 %) MM 
patients treated with acute HD, chronic HD and 
PE (Table 2)..
Table 2. Distribution of patients according to the type of treatment - acute or chronic haemodialysis 
(AHD or CHD) or plasma exchange (PE) (N = 43) 
Treatment n % 
AHD 12 28 
CHD 11 26 
PE 8 19 
AHD+PE 7 16 
CHD+PE 1 2 
AHD+CHD 1 2 
AHD+CHD+PE 3 7 
Total 43 100 
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Among 43 (29.9 %) MM patients who required HD 
or PE treatment, a total of 16 (37.2 %) patients 
were treated with chronic HD, including those 
treated with acute HD or PE in combination with 
chronic HD. Their median survival time was 11 
months (IQR 8 – 58). A total of 19 (44.2 %) MM 
patients were treated with acute HD, including 
those treated with chronic HD or PE in 
combination with acute HD and their median 
survival time was 2 months (IQR 1 – 5). Eight (18.6 
%) MM patients were treated only with PE and 
their median survival time was 1 month (IQR 0 – 
20). There was a significant difference in survival 




Figure 1. Kaplan- Meier plot of survival time (months) between the groups of patients who required 
haemodialysis (HD) or plasma exchange (PE) treatment. CHD includes multiple myeloma (MM) 
patients treated with chronic HD, including those treated with acute HD or PE in combination with 
chronic HD. Their median survival time was 11 months (IQR 8 – 58). AHD includes MM patients who 
were treated only with acute HD and those treated with a combination of acute HD and PE. Their 
median survival time was 2 months (IQR 1 – 5). PE encompasses MM patients who were treated only 
with PE and their median survival time was 1 month (IQR 0 – 20). There was a significant difference 
in survival time among the examined groups (P = 0.04). 
 
Survival time was calculated from the start of the 
treatment until the patient’s death.  
A total of 35 (81.4 %) MM patients were treated 
with HD, either only HD or in combination with 
PE, and their median survival time was 7 months 
(IQR 2 – 12). There were 8 (18.6 %) MM patients 
treated only with PE and their median survival 
time was 1 month (IQR 0 – 20). There was no 
significant difference in survival time between 
those who were treated with HD (including 
patients treated only with HD or with a 
combination of HD and PE) and those treated 
only with PE (P = 0.39) (Figure 2)..
P 
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Figure 2. Kaplan-Meier plot of survival (months) between the groups of patients who were treated 
only with plasma exchange  (PE) and those treated with haemodialysis  (HD) (includes patients 
treated only with HD or with a combination of HD and PE). The median survival time of multiple 
myeloma (MM) patients treated with PE was 1 month (IQR 0 – 20). The median survival time of the 
other group was 7 months (IQR 2 – 12). There was no significant difference in survival time between 
these two groups (P = 0.39). 
 
Discussion 
Impairment of kidney function in MM patients 
requiring dialysis or PE was associated with a 
shorter life span than in MM patients without 
such treatments. Patients who had no need for 
treatment with HD or PE were older at the time 
of death than the patients who needed such 
treatment, as we had assumed. The need for 
dialysis or PE was accompanied by a poor 
outcome in terms of life span in general. At the 
moment of our research, the outcome of the 
treatment was negative (death of the patient) in 
95 (66 %) cases; significantly, 34 (79.1 %) of these 
patients needed PE and/or HD. 
CKD often appears in MM patients. Despite 
aggressive treatment, 65 % of MM patients with 
kidney damage will reach the end-stage renal 
disease within three months of their MM 
diagnosis (7). Studies have shown that mortality 
and morbidity are more common among 
patients who need renal replacement therapy 
(RRT) than among those with regular kidney 
function (8). These findings correspond with our 
results.  
Some research has demonstrated that patients 
with MM and impairment of kidney function can 
be treated either with HD or PE and that these 
procedures are equally effective (9). On the 
other hand, one retrospective study suggested 
that PE might be helpful in preventing the 
initiation or continuation of dialysis in patients 
with rapidly progressive renal failure which 
occurred due to MM (10). More recent studies 
have suggested that PE in combination with 
chemotherapy, especially bortezomib, leads to 
renal improvement (11, 12). In this research, 
among the patients who needed HD or PE, the 
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17 patients who were treated with chronic HD 
lived the longest. Studies conducted at different 
centres found contrasting results. Therefore, in 
the future, research on this issue should be 
conducted on a larger number of subjects to get 
the most accurate results. 
Our research was a retrospective epidemiologic 
study. It should be noted that there were some 
limitations of this study due to data scarcity for 
the group without HD or PE treatment, which can 
account for some of the differences between 
our research and studies conducted by other 
researchers. There were missing facts about the 
time when the diagnoses of MM were 
confirmed, stage and type of MM, presence of 
kidney failure in those without non-conservative 
treatment, presence of other complications and 
methods of pharmacological treatment. 
However, the results of our research are 
important in analysing the outcomes of 
treatment at one centre and they show the 
negative association of kidney failure as well as 
other methods of treatment with non-
conservative procedures on lifespan and death 
outcome. It is also important to emphasize that 
there has been no similar research published by 
other centres. 
Conclusion  
Our study has shown that the requirement of 
chronic HD is related to a better outcome than 
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